restrict the use of Rezulin (troglitazone) for diabetes

May 1999

The FDA may further restrict the use of Rezulin (troglitazone) for diabetes...due to the risk of liver toxicity.

FDA advisors recommend NOT using Rezulin for monotherapy.

They also want the FDA to require patient package inserts...to explain the need for frequent liver function tests.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote